Research III on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: On Regulatory Requirements for Individual Case Safety Reports in Clinical Trials of Drugs

Feng Hongyun, Zhou Lingyun, Li Hao, Shao Ying, Lü Xinhuan, Yang Jianhong, Zuo Xiaochun

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 630-636.

Chinese Pharmaceutical Affairs ›› 2022, Vol. 36 ›› Issue (6) : 630-636. DOI: 10.16153/j.1002-7777.2022.06.005

Research III on Pharmacovigilance and Risk Control During Clinical Trials of New Drugs: On Regulatory Requirements for Individual Case Safety Reports in Clinical Trials of Drugs

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2022, 36(6): 630-636 https://doi.org/10.16153/j.1002-7777.2022.06.005

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉